Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial

Abdominal aortic aneurysm (AAA) may lead to rupture and death if left untreated. While endovascular or surgical repair is generally recommended for AAA greater than 5–5.5 cm, the vast majority of aneurysms detected by screening modalities are smaller than this threshold. Once discovered, there would...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ronald L Dalman, Ying Lu, Kenneth W Mahaffey, Amanda J Chase, Jordan R Stern, Robert W Chang
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2020
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/ec76d3d7fcbb4ba3b305629dcb7deb63
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ec76d3d7fcbb4ba3b305629dcb7deb63
record_format	dspace
spelling	oai:doaj.org-article:ec76d3d7fcbb4ba3b305629dcb7deb632021-12-04T16:03:16ZBackground and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial10.15420/ver.2020.032516-33022516-3299https://doaj.org/article/ec76d3d7fcbb4ba3b305629dcb7deb632020-07-01T00:00:00Zhttps://www.verjournal.com/articleindex/ver.2020.03https://doaj.org/toc/2516-3299https://doaj.org/toc/2516-3302Abdominal aortic aneurysm (AAA) may lead to rupture and death if left untreated. While endovascular or surgical repair is generally recommended for AAA greater than 5–5.5 cm, the vast majority of aneurysms detected by screening modalities are smaller than this threshold. Once discovered, there would be a significant potential benefit in suppressing the growth of these small aneurysms in order to obviate the need for repair and mitigate rupture risk. Patients with diabetes, in particular those taking the oral hypoglycaemic medication metformin, have been shown to have lower incidence, growth rate, and rupture risk of AAA. Metformin therefore represents a widely available, non-toxic, potential inhibitor of AAA growth, but thus far no prospective clinical studies have evaluated this. Here, we present the background, rationale, and design for a randomised, double-blind, placebo-controlled clinical trial of metformin for growth suppression in patients with small AAA.Ronald L DalmanYing LuKenneth W MahaffeyAmanda J ChaseJordan R SternRobert W ChangRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENVascular and Endovascular Review , Vol 3, Iss , Pp - (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Ronald L Dalman Ying Lu Kenneth W Mahaffey Amanda J Chase Jordan R Stern Robert W Chang Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
description	Abdominal aortic aneurysm (AAA) may lead to rupture and death if left untreated. While endovascular or surgical repair is generally recommended for AAA greater than 5–5.5 cm, the vast majority of aneurysms detected by screening modalities are smaller than this threshold. Once discovered, there would be a significant potential benefit in suppressing the growth of these small aneurysms in order to obviate the need for repair and mitigate rupture risk. Patients with diabetes, in particular those taking the oral hypoglycaemic medication metformin, have been shown to have lower incidence, growth rate, and rupture risk of AAA. Metformin therefore represents a widely available, non-toxic, potential inhibitor of AAA growth, but thus far no prospective clinical studies have evaluated this. Here, we present the background, rationale, and design for a randomised, double-blind, placebo-controlled clinical trial of metformin for growth suppression in patients with small AAA.
format	article
author	Ronald L Dalman Ying Lu Kenneth W Mahaffey Amanda J Chase Jordan R Stern Robert W Chang
author_facet	Ronald L Dalman Ying Lu Kenneth W Mahaffey Amanda J Chase Jordan R Stern Robert W Chang
author_sort	Ronald L Dalman
title	Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
title_short	Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
title_full	Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
title_fullStr	Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
title_full_unstemmed	Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial
title_sort	background and proposed design for a metformin abdominal aortic aneurysm suppression trial
publisher	Radcliffe Medical Media
publishDate	2020
url	https://doaj.org/article/ec76d3d7fcbb4ba3b305629dcb7deb63
work_keys_str_mv	AT ronaldldalman backgroundandproposeddesignforametforminabdominalaorticaneurysmsuppressiontrial AT yinglu backgroundandproposeddesignforametforminabdominalaorticaneurysmsuppressiontrial AT kennethwmahaffey backgroundandproposeddesignforametforminabdominalaorticaneurysmsuppressiontrial AT amandajchase backgroundandproposeddesignforametforminabdominalaorticaneurysmsuppressiontrial AT jordanrstern backgroundandproposeddesignforametforminabdominalaorticaneurysmsuppressiontrial AT robertwchang backgroundandproposeddesignforametforminabdominalaorticaneurysmsuppressiontrial
_version_	1718372768286769152

Background and Proposed Design for a Metformin Abdominal Aortic Aneurysm Suppression Trial

Ejemplares similares